Search Result

Results for "

extracellular+domain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Aldehyde Dehydrogenase (ALDH) (1) Amyloid-β (1) Apoptosis (2) Biochemical Assay Reagents (1) c-Kit (1) c-Met/HGFR (2) CCR (1) CD19 (1) CD3 (1) Claudin (1) CTLA-4 (1) CXCR (2) Discoidin Domain Receptor (1) Drug Derivative (1) Drug Intermediate (1) EGFR (7) ERK (1) Exosomes (1) FGFR (1) Fluorescent Dye (1) GLP Receptor (1) HCV (1) Interleukin Related (2) MDM-2/p53 (1) mTOR (1) Mucin (1) Na+/K+ ATPase (2) Notch (2) PD-1/PD-L1 (2) PI3K (1) PKA (1) Proton Pump (1) Reference Standards (1) RSV (2) TGF-beta/Smad (2) TGF-β Receptor (3) TNF Receptor (3) Transferrin Receptor (1) Transmembrane Glycoprotein (3) Trk Receptor (1) TSH Receptor (1) VEGFR (2)
By Research Areas:	Cancer (32) Cardiovascular Disease (7) Infection (4) Inflammation/Immunology (7) Metabolic Disease (5) Neurological Disease (7)

By Targets:

Akt (1)

Aldehyde Dehydrogenase (ALDH) (1)

Amyloid-β (1)

Apoptosis (2)

Biochemical Assay Reagents (1)

c-Kit (1)

c-Met/HGFR (2)

CCR (1)

CD19 (1)

CD3 (1)

Claudin (1)

CTLA-4 (1)

CXCR (2)

Discoidin Domain Receptor (1)

Drug Derivative (1)

Drug Intermediate (1)

EGFR (7)

ERK (1)

Exosomes (1)

FGFR (1)

Fluorescent Dye (1)

GLP Receptor (1)

HCV (1)

Interleukin Related (2)

MDM-2/p53 (1)

mTOR (1)

Mucin (1)

Na+/K+ ATPase (2)

Notch (2)

PD-1/PD-L1 (2)

PI3K (1)

PKA (1)

Proton Pump (1)

Reference Standards (1)

RSV (2)

TGF-beta/Smad (2)

TGF-β Receptor (3)

TNF Receptor (3)

Transferrin Receptor (1)

Transmembrane Glycoprotein (3)

Trk Receptor (1)

TSH Receptor (1)

VEGFR (2)

By Research Areas:

Cancer (32)

Cardiovascular Disease (7)

Infection (4)

Inflammation/Immunology (7)

Metabolic Disease (5)

Neurological Disease (7)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

HY-P99507

Zenocutuzumab MCLA-128; PB4188; R040517	EGFR	Cancer
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .

HY-12283

Rostafuroxin 2 Publications Verification PST 2238	Na+/K+ ATPase RSV	Cardiovascular Disease
Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na ⁺,K ⁺-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity .

HY-P9968

Nimotuzumab 1 Publications Verification h-R3	EGFR	Cancer
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-P991202

Anti-TSHR Antibody (M22)	TSH Receptor PKA	Metabolic Disease Inflammation/Immunology
Anti-TSHR Antibody (M22) is a selective agonist targeting TSHR (thyroid-stimulating hormone receptor), acting through competitive binding to the extracellular domain of TSHR. Anti-TSHR Antibody (M22) can mimic the biological effects of thyroid-stimulating hormone (TSH), activating downstream cAMP-PKA and other signaling pathways. Anti-TSHR Antibody (M22) can stimulate the proliferation of thyroid follicular epithelial cells and human umbilical vein endothelial cells (HUVECs), promote angiogenesis and tube formation, cell migration, and also upregulate the expression of angiogenesis-related proteins such as PROX1. Anti-TSHR Antibody (M22) can be used in research areas such as the mechanisms of goiter formation in Graves' disease (GD), angiogenesis regulation, and TSHR antagonist screening .

HY-P99480

Bintrafusp alfa M7824; MSB0011359C	TGF-β Receptor	Cancer
Bintrafusp alfa (M 7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII fused to a human IgG1 mAb blocking programmed cell death ligand. Bintrafusp alfa can be used for the research of cancer .

HY-P991558

RO-5429083 RG-7356	Transmembrane Glycoprotein	Cancer
RO-5429083 (RG-7356) is a humanized monoclonal antibody targeting CD44. RO-5429083 binds to the extracellular domain of CD44 and inhibits constitutive EGFR phosphorylation. RO-5429083 suppresses tumor growth in xenograft models and can be used in research related to head and neck squamous cell carcinoma and acute myeloid leukemia .

HY-P99437

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .

HY-153268

Silevertinib 2 Publications Verification BDTX-1535; EGFR-IN-76	EGFR	Infection Neurological Disease Metabolic Disease Cancer
Silevertinib (BDTX-1535) is an irreversible, brain-penetrant, selective and orally active EGFR inhibitor with wild-type EGFR-sparing. Silevertinib targets key EGFR resistance mutations, including the kinase domain (C797S, L718Q, G724S, S768I), extracellular domain (EGFRvIII, A289X), and EGFR amplification. Silevertinib exerts anti-tumor activity with well tolerated in vivo. Silevertinib can be used for non-small cell lung cancer (NSCLC) and glioblastoma (GBM) research .

HY-18377

Bioymifi 1 Publications Verification DR5 Activator	TNF Receptor Apoptosis	Cancer
Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a K_d of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .

HY-P11056

REF1 peptide	MDM-2/p53	Others
REF1 peptide is a PORK1 agonist with an EC₅₀ of 0.028 nM in tomato. REF1 peptide binds to the extracellular domain of PORK1, triggers receptor autophosphorylation, and drives downstream MPK3/MPK6 activation, thereby initiating defense and regeneration signaling cascades. REF1 peptide induces callus formation, inhibits shoot regeneration upon continuous exposure, and enhances the regeneration and transformation efficiency of recalcitrant dicotyledonous and monocotyledonous crops .

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

HY-P990017

Englumafusp alfa CD19-4-1BBL; RO7227166; RG6076	CD19	Cancer
Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .

HY-P991180

TRX-518	TNF Receptor	Cancer
TRX-518 is a humanized agylcosyl IgG1 anti-GITR mAb, , and is a GITR agonist. TRX-518 binds to the extracellular domain of human GITR, abrogates Treg-mediated suppression. TRX-518 increases effector T cell activation and pro-inflammatory cytokine production, reduces circulating and intratumor Treg frequencies. TRX-518 destabilizes Treg phenotype via Foxp3 downregulation and T-bet upregulation. TRX-518 can be used for the research of solid tumors^[1][2][3].

HY-P1985

Notch 1	Notch	Cardiovascular Disease Cancer
Notch 1 (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types .

HY-P99962

Surzebiclimab BGB-A425	Mucin	Cancer
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against *T-cell* immunoglobulin and mucin-domain containing-3 (TIM-3)*. Surzebiclimab binds to the extracellular domain* of human Tim-3 with high affinity (K_D=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .

HY-P99720A

Luspatercept (mIgG2a) RAP-536	TGF-beta/Smad	Metabolic Disease
Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .

HY-P5421

Caloxin 1B1	Proton Pump	Others
Caloxin 1B1 is a biological active peptide. (Caloxin 1b1 is obtained by screening for binding to extracellular domain 1 of PMCA4, which inhibited PMCA extracellularly, selectively, and had a higher affinity for PMCA4 than PMCA1. Because caloxin 1b1 had been selected to bind to an extracellular domain of PMCA, it could be added directly to cells and tissues to examine its effects on smooth muscle and endothelium.)

HY-P990130

Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26)	Transferrin Receptor	Neurological Disease
Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) is a mouse-derived IgG2a κ type antibody, targeting to mouse/rat CD71/TfR1. Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) targets the transferrin receptor and binds to an extracellular domain for the transferrin receptor. Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) can be used for the research in drug delivery, especially for drug delivery to the brain .

HY-N2452

Cochinchinenin C	GLP Receptor	Cardiovascular Disease Infection Metabolic Disease
Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions .

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa also functions as a PD-L1 inhibitor and a VEGF inhibitor .

HY-P990720

Elritercept KER-050	TGF-beta/Smad	Inflammation/Immunology
Elritercept (KER-050) is a recombinant fusion protein comprising a modified activin receptor type IIA extracellular domain fused to a human IgG1 Fc. Elritercept inhibits activin A and other select TGF-β superfamily ligands .

HY-P1985A

Notch 1 TFA	Notch	Cardiovascular Disease Cancer
Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types .

HY-P9968A

Nimotuzumab (powder)	EGFR	Cancer
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-121817

Sulfiram	Aldehyde Dehydrogenase (ALDH) Drug Intermediate Amyloid-β	Infection Neurological Disease
Sulfiram is a very weak aldehyde dehydrogenase (ALDH) inhibitor, with an IC₅₀ value of 413 μM against Saccharomyces cerevisiae ALDH. As a photochemical precursor, Sulfiram undergoes photoconversion to form Disulfiram (HY-B0240), a potent ALDH inhibitor. Sulfiram inhibits the dimerization of the extracellular domain fragment (amino acid residues 230-624) of amyloid precursor protein (APP), alters the monomer-dimer equilibrium, induces conformational changes in the fragment, and enhances the production of sAPPα via α-cleavage of APP. Sulfiram can be used in research related to scabies and Alzheimer's disease .

HY-P10495

GPR110 peptide agonist P12	Transmembrane Glycoprotein	Others Cancer
GPR110 peptide agonist P12 is a peptide that acts as a GPR110 agonist. GPR110 peptide agonist P12 can significantly enhance the initial rate of GPR110 stimulated G protein GTPγS binding. GPR110 peptide agonist P12 mimics the action of natural ligands, causing the extracellular domain (ECD) of the GPR110 to dissociate from the seven transmembrane domains (7TM), exposing the β-strand-13/stalk region at the N-terminus of the 7TM domain, which acts as an agonist to activate G protein signaling. GPR110 peptide agonist P12 can be used in the study of developmental disorders and cancers related to GPR110 .

HY-P991680

Elipunercept	TNF Receptor	Inflammation/Immunology
Elipunercept is a fusion protein that combines human TNFRSF1B extracellular domain fragment (1-235) fused at the C-terminus to a human IgG1 Fc fragment. Elipunercept is an immunomodulator .

HY-P991158

Rinvatercept	TGF-β Receptor	Neurological Disease
Rinvatercept, a fusion protein, is a glycyl (1)-chimeric N-terminal (1-108)-peptide (2-109) combined from the sequences of the extracellular domains of the human ACVR2A/B, and is fused via a G3 peptide linker (110-112) to an immunoglobulin G1 (IgG1) Fc fragment. Rinvatercept can be used for research of neuromuscular disease .

HY-P991572

MM-151	EGFR	Cancer
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .

HY-P991084

TQB-2858	PD-1/PD-L1	Cancer
TQB-2858 is a bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of TGF-β receptor. TQB-2858 has a high affinity for PD-L1, TGF-β1, and TGF-β3 and exhibited high PD-L1 target occupancy. TQB-2858 can be used for the study of osteosarcoma and alveolar soft part sarcoma (ASPS) .

HY-E70869

TRKA(NTRK1) Recombinant Human Active Protein Kinase	Trk Receptor	Neurological Disease
TRKA (also named NTRK1) is a potential new member of the tyrosine kinase gene family. TRKA is a receptor tyrosine kinase that is phosphorylated in response to NGF. A single transmembrane domain divides TRKA into an extracellular domain, important for NGF binding, and an intracellular tyrosine kinase domain, important for signal transduction. TRKA(NTRK1) Recombinant Human Active Protein Kinase is a recombinant TRKA(NTRK1) protein that can be used to study TRKA(NTRK1)-related functions .

HY-P990851

Anti-c-Kit/CD117 Antibody (SR-1)	c-Kit	Inflammation/Immunology Cancer
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human c-Kit/CD117. Anti-c-Kit/CD117 Antibody (SR-1) binds to the extracellular domain of human c-Kit (also known as CD117) and blocks stem cell factor (SCF) binding to CD117. Anti-c-Kit/CD117 Antibody (SR-1) can be used for the researches of cancer and immunology, such as gastrointestinal stromal tumor (GIST) and xenograft .

HY-P10833

C-VGB3	VEGFR PI3K Akt mTOR ERK Apoptosis	Cardiovascular Disease Cancer
C-VGB3 is a selective vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer .

HY-P990986

Efdelikofusp alfa	Interleukin Related	Inflammation/Immunology Cancer
Efdelikofusp alfa is a bispecific Fc fusion protein. Efdelikofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efdelikofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.

HY-12283R

Rostafuroxin (Standard) PST 2238 (Standard)	Na+/K+ ATPase RSV Reference Standards	Cardiovascular Disease
Rostafuroxin (Standard) is the analytical standard of Rostafuroxin. This product is intended for research and analytical applications. Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na+,K+-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity .

HY-P990992

Efzilonkofusp alfa GI-102	Interleukin Related	Inflammation/Immunology Cancer
Efzilonkofusp alfa is a bispecific Fc fusion protein. Efzilonkofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efzilonkofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.

HY-P5472

Tumour-associated MUC1 epitope	Transmembrane Glycoprotein	Others
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)

HY-P991233

BAT1006	EGFR	Cancer
BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .

HY-E70717

FGFR1 V561M Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR1 has been implicated in numerous cancer types including non-small cell lung cancer (NSCLC). FGFR1 is activated upon FGF binding to its extracellular domain, resulting in protein dimerization and transautophosphorylation of the intracellular tyrosine kinase domains. FGFR1 V561M gatekeeper mutation drives Fexagratinib (AZD4547) (HY-13330) resistance through STAT3 Activation and EMT. FGFR1 V561M Recombinant Human Active Protein Kinase is a recombinant FGFR1 V561M protein that can be used to study FGFR1 V561M-related functions .

HY-P991746

Anti-Mouse CXCR2 Antibody (Cx2Mab-1)	CXCR	Cancer
Anti-Mouse CXCR2 Antibody (Cx2Mab-1) reacts with mouse CXCR2 targeting the N-terminal extracellular domain of CXCR2. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-D3352

EMI-137 AGSCYCSGPPRFECWCYETEGT-Cy5	Fluorescent Dye c-Met/HGFR	Cancer
EMI-137 (AGSCYCSGPPRFECWCYETEGT-Cy5) is a fluorescent imaging agent targeting the c-Met receptor. EMI-137 specifically binds to the extracellular domain of the c-Met receptor and is used for fluorescent visualization of c-Met-expressing cells and tissues. EMI-137 can be applied to research related to colorectal cancer .

HY-P991752

Anti-Mouse CXCL16 Antibody (12-81)	CXCR	Cancer
Anti-Mouse CXCL16 Antibody (12-81) reacts with the extracellular domain of CXCL16. Anti-Mouse CXCL16 Antibody (12-81) can neutralize CXCL16/SR-PSOX both in vitro and in vivo. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979) .

HY-P992481

VERT-002	c-Met/HGFR	Cancer
VERT-002 is a MET degrader and monoclonal antibody. VERT-002 induces nearly complete and profound degradation of the MET protein by enhancing the intrinsic shedding of the MET extracellular domain (ECD). VERT-002 demonstrates significant anti-tumor activity. VERT-002 can be used in non-small cell lung cancer research. .

HY-P11741

BV2	Exosomes Biochemical Assay Reagents	Neurological Disease
BV2 is a delivery peptide that binds to BVES, with a K_a of 2.03 μM for the BVES target. BV2 specifically binds to the extracellular domain of BVES, achieving muscle homing and cellular internalization via caveolae-mediated endocytosis. When BV2 is modified on the surface of exosomes by PMO, it enhances dystrophin restoration in the peripheral muscles and myocardium of dystrophin-deficient mice. BV2 is applicable to research related to Duchenne muscular dystrophy and muscle atrophy .

HY-P991961

REGN4659	CTLA-4	Cancer
REGN4659 is a fully human anti-CTLA-4 monoclonal antibody and IgG1 antibody. REGN4659 binds to the extracellular domain of human and monkey CTLA-4 with high affinity and specificity. REGN4659 blocks CTLA-4 interaction with CD80 and CD86 ligands. REGN4659 significantly suppresses MC38.Ova tumor growth in CTLA-4 knock-in mice .

HY-P992381

IBI352g4a	Drug Derivative	Cancer
IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (K_d = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .

HY-P991855

RKER-216	TGF-β Receptor	Metabolic Disease
RKER-216 is a human monoclonal IgG antibody inhibitor targeting ALK2 with a K_D of 58.7 pM. RKER-216 reduces hepcidin transcription in Hep3B.RKER-216 competes with BMP ligands for binding to the extracellular domain of ALK2, thereby inhibiting BMP-SMAD signal. RKER-216 mobilizes tissue iron effectively in inflammatory conditions. RKER-216 improves microcytic anemia in a dose-dependent manner by inhibiting SMAD signaling to reduce hepcidin and promote iron absorption and utilization in vivo. RKER-216 can be used for research on anemia of inflammation .

HY-P992365

HFB101110	CCR	Cancer
HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties .

HY-P992066

Anti-Mouse DDR2 Antibody (DAB0065)	Discoidin Domain Receptor	Inflammation/Immunology
Anti-Mouse DDR2 Antibody (DAB0065) is a mAb that specifically targets mouse discoidin domain receptor DDR2 without cross-reacting with DDR1. Anti-Mouse DDR2 Antibody (DAB0065) binds to the extracellular domain of native mouse DDR2, induces endocytosis and lysosomal degradation of DDR2, and this process is independent of collagen binding. Anti-Mouse DDR2 Antibody (DAB0065) exhibits significant therapeutic effects in both the unilateral ureteral obstruction (UUO) mouse model of renal fibrosis and the bleomycin (HY-108345)-induced mouse model of pulmonary fibrosis, effectively downregulating the mRNA expression of type I collagen Col1a1 and fibronectin Fn1. Anti-Mouse DDR2 Antibody (DAB0065) can be humanized and has the potential to be developed as a targeted agent for diseases such as idiopathic pulmonary fibrosis and renal fibrosis .

Cat. No.	Product Name	Target	Research Area